Brain 17 Vienna
PROFILE trials 1005 & 1007
ALK+ advanced NSCLC & brain metastases
brain mets previously untreated
no brain mets
no. pts
166
613
PFS median
5.9m (4.2-6.9) 77% (67-85)
8.8m (7.9-9.9) 85% (81-87)
6 m OS
613 patients
275 patients
Brain metastases in patients with ALK-positive NSCLC
Costa et al 2015, J Clin Oncol; 33 (17): 1881-1888
Made with FlippingBook - Online catalogs